RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Elite Pharmaceuticals Stock

Elite Pharmaceuticals P/S 2024

Elite Pharmaceuticals P/S

3.06

Ticker

ELTP

ISIN

US28659T2006

WKN

634826

As of Nov 4, 2024, Elite Pharmaceuticals's P/S ratio stood at 3.06, a 194.23% change from the 1.04 P/S ratio recorded in the previous year.

The Elite Pharmaceuticals P/S history

Elite Pharmaceuticals Aktienanalyse

What does Elite Pharmaceuticals do?

Elite Pharmaceuticals Inc is an American pharmaceutical company that focuses on the development and manufacturing of generic and specialty pharmaceutical products. The company was founded in 1984 and is headquartered in Northvale, New Jersey. Elite Pharmaceuticals has become a leading company in the industry over the years and is known for its innovative products and tailored solutions. The company works closely with customers and business partners to understand market needs and develop products that meet the highest quality standards. Its business model is based on creating partnerships with other companies and organizations to bring its products to market. Elite Pharmaceuticals consists of two divisions: generic and specialty pharmaceuticals. The generic division focuses on the development and manufacturing of generic medications that contain the same active ingredient and dosage as brand-name products. The company produces a wide range of generic medications, including drugs for the treatment of cardiovascular disease, infections, pain, and inflammation. The specialty division focuses on the development and manufacturing of specialty pharmaceutical products for difficult-to-treat diseases. The company specializes in developing products for patients with inadequately treated conditions, including pain management, Parkinson's disease, sleep disorders, and attention deficit hyperactivity disorder (ADHD). An example of a specialty product from Elite Pharmaceuticals is Vycapri, a medication used to treat Parkinson's disease. Vycapri is a product developed in collaboration with SunGen Pharma and is currently in the third phase of clinical development. The medication aims to improve the management of Parkinson's disease by reducing symptoms such as muscle stiffness, tremors, and slow movements. Elite Pharmaceuticals Inc has demonstrated through its continuous research and development and partnerships with other companies in the industry that it is an innovative company playing an important role in the pharmaceutical product market. The company is committed to manufacturing and advancing products of the highest quality and efficacy to meet the needs of its customers and patients. Elite Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Elite Pharmaceuticals's P/S Ratio

Elite Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Elite Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Elite Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Elite Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Elite Pharmaceuticals stock

What is the price-to-earnings ratio of Elite Pharmaceuticals?

The price-earnings ratio of Elite Pharmaceuticals is currently 3.06.

How has the price-earnings ratio of Elite Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Elite Pharmaceuticals has increased by 194.23% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Elite Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Elite Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Elite Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Elite Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Elite Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Elite Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Elite Pharmaceuticals?

Some factors that influence the price-earnings ratio of Elite Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Elite Pharmaceuticals pay?

Over the past 12 months, Elite Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Elite Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Elite Pharmaceuticals?

The current dividend yield of Elite Pharmaceuticals is .

When does Elite Pharmaceuticals pay dividends?

Elite Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Elite Pharmaceuticals?

Elite Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Elite Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Elite Pharmaceuticals located?

Elite Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Elite Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Elite Pharmaceuticals from 11/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did Elite Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of Elite Pharmaceuticals in the year 2023?

In the year 2023, Elite Pharmaceuticals distributed 0 USD as dividends.

In which currency does Elite Pharmaceuticals pay out the dividend?

The dividends of Elite Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Elite Pharmaceuticals

Our stock analysis for Elite Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Elite Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.